Weiss K C, Linder M C
Am J Physiol. 1985 Jul;249(1 Pt 1):E77-88. doi: 10.1152/ajpendo.1985.249.1.E77.
The time course of distribution of high-specific activity 67CuCl2 to tissues and plasma components was followed in adult, female rats. Immediately after intubation or injection, tracer 67Cu associated with two components of the blood plasma separable on columns of Sephadex G-150: albumin and another (larger) component, which was not ceruloplasmin. The latter, tentatively named transcuprein, had an apparent molecular weight of 270,000 and a high affinity for Cu2+, as judged by processing through Chelex-100, dilution, and exchange with albumin copper, in vitro and in vivo. It was capable of donating copper to tumor cells in serum-free medium. Analysis of "cold" plasma by furnace atomic absorption confirmed the presence of 10-15% of plasma copper in this peak. Plots of percent dose and 67Cu specific activity against time showed that copper followed a very specific pathway after binding to albumin and transcuprein, entering mainly the liver, then reappearing in the plasma on ceruloplasmin, and then achieving peak distribution in peripheral tissues (muscles, brain, etc.). 67Cu disappeared from liver and kidney with an apparent half-life of 4.5 days, the same exponential rate found for whole body turnover. Apparent turnover of ceruloplasmin copper was more rapid. Even after 7-12 days, tracer copper in plasma was still found exclusively with ceruloplasmin. The results indicate that copper follows a carefully prescribed path, on entering the blood and binding to a new transport protein.
在成年雌性大鼠中追踪了高比活度67CuCl2在组织和血浆成分中的分布时程。插管或注射后立即发现,示踪剂67Cu与血浆中的两种成分相关,这两种成分可在Sephadex G - 150柱上分离:白蛋白和另一种(较大的)成分,后者不是铜蓝蛋白。后者暂命名为转铜蛋白,通过在体外和体内用Chelex - 100处理、稀释以及与白蛋白铜交换判断,其表观分子量为270,000,对Cu2+具有高亲和力。它能够在无血清培养基中向肿瘤细胞提供铜。通过火焰原子吸收法对“冷”血浆进行分析,证实该峰中存在10 - 15%的血浆铜。剂量百分比和67Cu比活度随时间的曲线表明,铜在与白蛋白和转铜蛋白结合后遵循非常特定的途径,主要进入肝脏,然后在铜蓝蛋白上重新出现在血浆中,随后在外周组织(肌肉、脑等)中达到分布峰值。67Cu从肝脏和肾脏消失的表观半衰期为4.5天,这与全身周转的指数速率相同。铜蓝蛋白铜的表观周转更快。即使在7 - 12天后,血浆中的示踪铜仍仅在铜蓝蛋白中被发现。结果表明,铜进入血液并与一种新的转运蛋白结合后遵循一条精心规定的路径。